| A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution SV Ramagopalan, A Heger, AJ Berlanga, NJ Maugeri, MR Lincoln, ... Genome research 20 (10), 1352-1360, 2010 | 1097 | 2010 |
| Expression of the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1*1501 Is Regulated by Vitamin D SV Ramagopalan, NJ Maugeri, L Handunnetthi, MR Lincoln, SM Orton, ... PLoS genetics 5 (2), e1000369, 2009 | 687 | 2009 |
| Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection M Patone, XW Mei, L Handunnetthi, S Dixon, F Zaccardi, M Shankar-Hari, ... Nature medicine 28 (2), 410-422, 2022 | 513 | 2022 |
| An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis AE Handel, AJ Williamson, G Disanto, L Handunnetthi, G Giovannoni, ... PloS one 5 (9), e12496, 2010 | 478 | 2010 |
| Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection M Patone, L Handunnetthi, D Saatci, J Pan, SV Katikireddi, S Razvi, ... Nature medicine 27 (12), 2144-2153, 2021 | 323 | 2021 |
| Regulation of major histocompatibility complex class II gene expression, genetic variation and disease L Handunnetthi, SV Ramagopalan, GC Ebers, JC Knight Genes & Immunity 11 (2), 99-112, 2010 | 175 | 2010 |
| A genetics-led approach defines the drug target landscape of 30 immune-related traits H Fang, H De Wolf, B Knezevic, KL Burnham, J Osgood, A Sanniti, ... Nature genetics 51 (7), 1082-1091, 2019 | 166 | 2019 |
| Multiple sclerosis, vitamin D, and HLA-DRB1*15 L Handunnetthi, SV Ramagopalan, GC Ebers Neurology 74 (23), 1905-1910, 2010 | 146 | 2010 |
| Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex M Patone, XW Mei, L Handunnetthi, S Dixon, F Zaccardi, M Shankar-Hari, ... Circulation 146 (10), 743-754, 2022 | 142 | 2022 |
| Heterogeneity in multiple sclerosis: scratching the surface of a complex disease G Disanto, AJ Berlanga, AE Handel, AE Para, AM Burrell, A Fries, ... Autoimmune diseases 2011, 2010 | 131 | 2010 |
| Prodromal symptoms of multiple sclerosis in primary care G Disanto, C Zecca, S MacLachlan, R Sacco, L Handunnetthi, UC Meier, ... Annals of neurology 83 (6), 1162-1173, 2018 | 130 | 2018 |
| Perceptual systems controlling speech production NS Dhanjal, L Handunnetthi, MC Patel, RJS Wise Journal of Neuroscience 28 (40), 9969-9975, 2008 | 115 | 2008 |
| Genetic and environmental factors and the distribution of multiple sclerosis in Europe AE Handel, L Handunnetthi, G Giovannoni, GC Ebers, SV Ramagopalan European Journal of Neurology 17 (9), 1210-1214, 2010 | 102 | 2010 |
| Risk alleles for multiple sclerosis in multiplex families MJ D’netto, H Ward, KM Morrison, SV Ramagopalan, DA Dyment, ... Neurology 72 (23), 1984-1988, 2009 | 87 | 2009 |
| Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians SM Orton, SV Ramagopalan, AE Para, MR Lincoln, L Handunnetthi, ... Journal of the neurological sciences 305 (1-2), 116-120, 2011 | 84 | 2011 |
| MHC transmission: insights into gender bias in MS susceptibility MJ Chao, SV Ramagopalan, BM Herrera, SM Orton, L Handunnetthi, ... Neurology 76 (3), 242-246, 2011 | 79 | 2011 |
| The emerging role of vitamin D binding protein in multiple sclerosis G Disanto, SV Ramagopalan, AE Para, L Handunnetthi Journal of neurology 258, 353-358, 2011 | 65 | 2011 |
| Type 1 diabetes mellitus and multiple sclerosis: common etiological features AE Handel, L Handunnetthi, GC Ebers, SV Ramagopalan Nature Reviews Endocrinology 5 (12), 655-664, 2009 | 51 | 2009 |
| Prevalence of primary outcome changes in clinical trials registered on ClinicalTrials. gov: a cross-sectional study S Ramagopalan, AP Skingsley, L Handunnetthi, M Klingel, D Magnus, ... F1000Research 3, 2014 | 47 | 2014 |
| The effect of single nucleotide polymorphisms from genome wide association studies in multiple sclerosis on gene expression AE Handel, L Handunnetthi, AJ Berlanga, CT Watson, JM Morahan, ... PloS one 5 (4), e10142, 2010 | 43 | 2010 |
Julian KnightProfessor of Genomic Medicine, University of OxfordVerified email at well.ox.ac.uk
